A Randomized, Phase 1b/2 Trial of Rilotumumab or Ganitumab in Combination With Panitumumab Versus Panitumumab Alone in Subjects With Wild-Type KRAS Metastatic Colorectal Cancer

Trial Profile

A Randomized, Phase 1b/2 Trial of Rilotumumab or Ganitumab in Combination With Panitumumab Versus Panitumumab Alone in Subjects With Wild-Type KRAS Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs Ganitumab (Primary) ; Rilotumumab (Primary) ; Panitumumab
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 22 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 28 Apr 2012 Planned number of patients changed from 132 to 153 as reported by European Clinical Trials Database.
    • 25 Jun 2011 Results presented at the 13th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top